Business Wire

THALES

18.2.2021 16:56:12 CET | Business Wire | Press release

Share
French Armed Forces to Rely on Thales Expertise to Expand Their Secure Satellite Communication Capabilities

Thales has been chosen by the French defence procurement agency (DGA) to lead a second part of the ground segment of the Syracuse IV satellite communications system for the French armed forces. The Group was selected to supply the satellites in 2015 and to lead the first increment of the ground segment in 2019. This second capacity increment will enhance the interoperable communications capabilities of the French Army, Navy and Air Force in terms of data rate, availability, threat resistance and end-to-end connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005759/en/

Military satellite communications are more critical than ever and more vulnerable to attack; they are at the heart of the battle for strategic independence across all areas of military invention. Maintaining connectivity is key to the armed forces' ability to share information of all types between command centres and units deployed on any type of mission, including coalition operations.

This crucial programme milestone will enhance the performance of the ground segment across all theatres of operation for the three branches of the French military. The Thales solution will decisive in meeting the capacity requirements of land, naval and air force programmes such as Scorpion, FREMM, FDI, Barracuda, aircraft carrier, or Rafale. It aims to increase tenfold the secure communication capabilities of fighting vehicles on the move, surface vessels, submarines, and now also aircrafts. The Thales technology guarantees roaming communications in both X- and Ka-band and fully exploits the multi-spot potential of High Throughput Satellite (HTS) technology.

All the ground terminals in the system will be able to make optimum use of the Syracuse IV constellation. Their full interconnection via new docking terminals will allow considerable increase in data rate by ensuring joint cooperation in theatres of operations and with command centres. They will also be compatible with third-party satellite resources, depending on the area of deployment, without compromising communications security.

To achieve this objective, Thales will leverage its high-level systems integration expertise, and in particular its highly secure Modem 21 transmission system, to guarantee the availability and confidentiality of all communications and provide protection from the full spectrum of threats with no impact on operational performance, which is key to retaining information superiority in high-intensity combat. Thales’s NATO-standard Modem 21 solution has been proven in combat for over ten years.

The role of Thales Alenia Space in this contract will include mission management for the Syracuse constellation and management of the anchoring capabilities of the operator, the French Defence Ministry's joint infrastructure networks and information systems agency (DIRISI). Thales Alenia Space is also lead contractor for the contract notified by the DGA at the end of 2015 for the supply of the space segment consisting of the Syracuse 4A and 4B satellites and their control and mission ground segment.

Building on its expertise as a technology orchestrator and integrator for satellite communication systems in France and internationally, Thales has deployed over 1,000 secure, protected satcom stations worldwide, working with local industrial partners.

“As prime contractor for the Syracuse III and Syracuse IV ground segments since 2004, Thales is proud to strengthen its partnership with the French Ministry for the Armed Forces to help maintain the informational superiority of the country’s armed forces in highly contested environments. The sovereign satcom solutions to be supplied under this contract are resilient to all types of threats, combat-proven, and fully interoperable with the systems deployed by NATO coalition forces.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales.

Note to editors

Syracuse is a series of protected telecommunication satellites designed to ensure that the French armed forces can communicate at all times between mainland France and units deployed around the world. The Syracuse programme provides a fully independent solution to France’s wide-ranging requirements for long-range, secure communication capabilities that are protected against electronic warfare threats. Three generations of Syracuse satellites were deployed between 1984 and 2015. The Syracuse IV programme will replace the Syracuse 3A and Syracuse 3B satellites currently in orbit, while delivering an expanded and upgraded network of ground stations. A constellation of two satellites has been ordered under the first phase of the Syracuse IV programme. They will be built by Thales Alenia Space and Airbus Defence and Space. The first satellite will enter service in 2022.

About Thales

Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers – businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).

PLEASE VISIT

Thales Group

Download photos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye